Skip to content

To know the effect of RUMA Spray in Acute Musculoskeletal Pain and Acute Sports Injury Pain

An Openâ??Label, Two Arm Clinical Study to Evaluate the Efficacy and Safety of RUMA Spray in Acute Musculoskeletal Pain and Acute Sports Injury Pain Relief

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032710
Enrollment
40
Registered
2021-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M95-M95- Other disorders of the musculoskeletal system and connective tissue

Interventions

Intervention1: RUMA Pain relief Spray for acute muscular pain and Acute sports injury.: Arm one is for Acute Muscular pain and Arm two is for Acute sports injury. RUMA Spray will be applied Maximum o

Sponsors

The Himalaya Drug Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects of either gender aged >=18 - 2.Subjects with Grade I and Grade II muscular sprains and joint pain. 3.Subjects suffering from Common musculoskeletal conditions - Back ache, joints pain (Wrist, elbow, shoulder, ankle, Knee, neck pain, sprains and strains / Sports and traumatic injuries. 4.Subjects willing to sign informed consent and follow with the schedule. 5.Subjects who have not participated in similar kind of study in last 4 weeks.

Exclusion criteria

Exclusion criteria: 1.subjects suffering from auto-immune disorders, spastic disorders, genetic disorders and severe traumatic conditions. 2.Any evidence or history of hypersensitivity to any of the components in the RUMA Spray 3.Any known skin disorder or presence of open wounds. 4.subjects who are taking any additional topical therapy or systemic NSAIDs. 5.Clinical diagnosis of bruises, trauma, muscle damage. 6.subjects with raw wounds, sutures, fractures and hematoma. 7.Pregnant or lactating women/women not willing to follow adequate standard contraceptive measures.

Design outcomes

Primary

MeasureTime frame
Time required for the onset of relief. Time required for complete relief. Time required for next successive application.Timepoint: quick relief

Secondary

MeasureTime frame
Improvement in the Visual Analogue Scale scoring on the successive application as compared to baseline. Incidence of any adverse events during study. Timepoint: 24 hours

Countries

India

Contacts

Public ContactDrSoorya Narayan H

The Himalaya Drug Company

dr.srikrishna@himalayawellness.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026